Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven?
作者信息
Lincoff A M, Topol E J
出版信息
Eur Heart J. 2000 Jun;21(11):863-7. doi: 10.1053/euhj.1999.1975.
PMID:10806004
Abstract
摘要
相似文献
1
Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven?
Eur Heart J. 2000 Jun;21(11):863-7. doi: 10.1053/euhj.1999.1975.
2
Introduction: glycoprotein IIb/IIIa blockers in the era of metallic coronaries.
J Invasive Cardiol. 2002 Dec;14 Suppl E:1E.
3
Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
N Engl J Med. 1999 Jul 29;341(5):319-27. doi: 10.1056/NEJM199907293410503.
4
IIb/IIIa platelet inhibitors in the management of coronary artery disease.
J Ark Med Soc. 1996 Oct;93(5):237-9.
5
[Glycoprotein IIb/IIIa antagonists].
Med Monatsschr Pharm. 2000 Dec;23(12):385-90.
6
[Theombolysis with GP IIb/IIIa-receptor blockader. Platelt aggregation inhibition: clear indications, new strategies].
Internist (Berl). 1998 Dec;39(12 Suppl Plattchena):1-4.
7
8
More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa-blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trials.
Eur Heart J. 1996 Mar;17(3):325-6. doi: 10.1093/oxfordjournals.eurheartj.a014858.
9
Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary interventions.
Indian Heart J. 2000 Sep-Oct;52(5):524-32.
10
Care of the patient receiving ReoPro following angioplasty.
J Invasive Cardiol. 1994;6 Suppl A:38A-42A; discussion 54A-56A.
Zotero 插件